{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:29:21Z","timestamp":1791923361636,"version":"4.3.4"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>\n              The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type\n              <jats:italic>TP53<\/jats:italic>\n              ; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with high-risk\n              <jats:italic>TP53<\/jats:italic>\n              aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with\n              <jats:italic>TP53<\/jats:italic>\n              aberration.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-na\u00efve CLL enriched for high-risk CLL, defined by\n              <jats:italic>TP53<\/jats:italic>\n              aberration (ClinicalTrials.gov identifier:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03580928\">NCT03580928<\/jats:ext-link>\n              ). Patients received acalabrutinib, obinutuzumab, and then venetoclax, with each treatment introduced sequentially and in combination, with the duration guided by measurable residual disease (MRD). Patients who achieved undetectable MRD (uMRD) after either 15 or 24 cycles could discontinue treatment. The primary end point was complete remission (CR) with bone marrow uMRD (BM-uMRD) at the start of cycle 16.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Seventy-two patients were accrued, including 45 patients with\n              <jats:italic>TP53<\/jats:italic>\n              aberration. The CR with BM-uMRD rates at the start of cycle 16 were 42% in patients with\n              <jats:italic>TP53<\/jats:italic>\n              aberration and 42% in all-comers, and the BM-uMRD rates were 71% and 78%, respectively. Hematologic toxicities were mainly low grade, and cardiovascular toxicities and bleeding complications were infrequent. After a median follow-up of 55.2 months, 10 patients had progressed, including four with transformation, and three patients died. Four-year progression-free survival and overall survival for patients with or without\n              <jats:italic>TP53<\/jats:italic>\n              aberration were 70%\/96% and 88%\/100%, respectively.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>AVO was highly active and well tolerated in patients with previously untreated high-risk CLL, supporting its use as a new standard-of-care treatment option.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco-24-02503","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:40:38Z","timestamp":1733622038000},"page":"788-799","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":41,"title":["Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Na\u00efve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03580928","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":true,"given":"Christine E.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-3363","authenticated-orcid":true,"given":"Benjamin L.","family":"Lampson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-6507","authenticated-orcid":true,"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":true,"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-0658","authenticated-orcid":true,"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Montegaard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1499-7039","authenticated-orcid":true,"given":"Claire","family":"Greenman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0180-0654","authenticated-orcid":true,"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":true,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-1603","authenticated-orcid":true,"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Lo","sequence":"additional","affiliation":[{"name":"Stamford Hospital, Stamford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":true,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Brown University Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Arnason","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-287X","authenticated-orcid":true,"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":true,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1908213"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0838"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1630"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030771"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187128"},{"key":"e_1_3_11_14_2","first-page":"EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater Arnon P","year":"2022","unstructured":"Kater Arnon P, Owen C, Moreno C, et al: Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 1:EVIDoa2200006, 2022","journal-title":"NEJM Evid"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020013"},{"key":"e_1_3_11_20_2","doi-asserted-by":"crossref","unstructured":"Brown J Seymour J Jurczak W et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter open-label randomized phase 3 AMPLIFY trial [abstract]. Presented at the 66th American Society of Hematology meeting December 7-10 2024. San Diego CA 2024","DOI":"10.1182\/blood-2024-200701"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00307-0"},{"key":"e_1_3_11_22_2","unstructured":"Jain N Atluri H Ferrajoli A et al. Combined pirtobrutinib venetoclax and obinutuzumab in first-line treatment of patients with chronic lymphocytic leukemia (CLL): A phase 2 trial [abstract]. Presented at the 29th European Hematology Association Congress June 13-16 2024. Madrid Spain. 2024"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0456"}],"updated-by":[{"DOI":"10.1200\/jco-25-00466","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000}},{"DOI":"10.1200\/jco-24-02716","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-02503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T19:59:16Z","timestamp":1742327956000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-02503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1200\/JCO-24-02503"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-02503","relation":{"correction":[{"id-type":"doi","id":"10.1200\/JCO-25-00466","asserted-by":"object"},{"id-type":"doi","id":"10.1200\/JCO-24-02716","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}